At Cell and Gene Therapy 2026 by Elrig, Drug Discovery & Development (DDD) sat down with Bio-Rad experts to discuss the analytical shift toward commercial-scale manufacturing.
As the industry moves from relative benchmarks to absolute molecular precision, the focus has intensified on meeting stringent regulatory compliance and standardised safety profiles.
Experts highlighted how droplet-partitioning technology addresses the critical challenge of quantifying residual host cell DNA and viral titres within complex biological matrices.
By providing high-sensitivity, 21 CFR Part 11-compliant data without the variability of traditional standard curves, these digital PCR solutions mitigate the risks of PCR inhibition, ensuring the purity and potency of genomic payloads and bridging the gap between clinical discovery and predictable patient outcomes.
